Approval of First CRISPR Medicine for Sickle Cell Disease

This chapter explores the recent approval of CASGIVI, the first CRISPR gene editing medicine in the U.S., for treating sickle cell disease. It also discusses the potential of Lifgenia, another gene treatment, and highlights the safety risks associated with it.